Journal of Oral and Maxillofacial Surgery
Volume 66, Issue 5 , Pages 839-847 , May 2008

Inhibition of Oral Mucosal Cell Wound Healing by Bisphosphonates

  • Regina Landesberg, DMD, PhD

      Affiliations

    • Associate Professor, Columbia University, College of Dental Medicine, Division of Oral and Maxillofacial Surgery, New York, NY.
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Landesberg: Columbia University, College of Dental Medicine, Division of Oral and Maxillofacial Surgery, 630 W 168th Street, Box 20, New York, NY 10032
    • ,
  • Matthew Cozin, BA

      Affiliations

    • Technician, Columbia University, College of Dental Medicine, Division of Oral and Maxillofacial Surgery, New York, NY.
    • ,
  • Serge Cremers, PhD

      Affiliations

    • Associate Research Scientist, Columbia University, College of Physicians and Surgeons, Department of Medicine, Division of Endocrinology, New York, NY.
    • ,
  • Victoria Woo, DDS

      Affiliations

    • Assistant Professor, Columbia University, College of Dental Medicine, Division of Oral and Maxillofacial Pathology, New York, NY.
    • ,
  • Stavroula Kousteni, PhD

      Affiliations

    • Assistant Professor, Columbia University, College of Physicians and Surgeons, Department of Medicine, Division of Endocrinology, New York, NY.
    • ,
  • Satrajit Sinha, PhD

      Affiliations

    • Associate Professor, School of Medicine and Biomedical Sciences, Department of Biochemistry, State University of New York at Buffalo, Buffalo, NY.
    • ,
  • LeeAnn Garrett-Sinha, PhD

      Affiliations

    • Assistant Professor, School of Medicine and Biomedical Sciences, Department of Biochemistry, State University of New York at Buffalo, Buffalo, NY.
    • ,
  • Srikala Raghavan, PhD

      Affiliations

    • Assistant Professor, Columbia University, College of Dental Medicine, Division of Oral and Maxillofacial Surgery, College of Physicians and Surgeons, Department of Dermatology, New York, NY.

References 

  1. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J. 2001;7:377
  2. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458
  3. Major P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist. 2002;7:481
  4. Van Poznak CH. The use of bisphosphonates in patients with breast cancer. Cancer Control. 2002;9:480
  5. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115
  6. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  7. Marx RE, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofacial Surg. 2005;63:1567
  8. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253
  9. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104
  10. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg. 2004;62:391
  11. Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity. Am J Med. 2004;117:440
  12. Hoff AO, Toth BB, Altundag V, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy (2006 ASCO Annual Meeting Proceedings Part I). J Clin Oncol. 2006;24(suppl):8528
  13. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055
  14. Bezzi M, Hasmim M, Bieler G, et al. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem. 2003;278:43603
  15. Hamma-Kourbali Y, Di Benedetto M, Ledoux D, et al. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun. 2003;310:816
  16. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004;114:623
  17. Okamoto T, Yamagishi S, Inagaki Y, et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun. 2002;297:419
  18. Santini D, Vincenzi B, Avcvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002;8:1080
  19. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369
  20. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology (American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma). J Clin Oncol. 2007;25:2464
  21. Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Prac. 2006;1:7
  22. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479
  23. Twiss IM, de Water R, den Hartigh J, et al. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci. 1994;83:699
  24. Twiss IM, Pas O, Rampkoopmanschap W, et al. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res. 1999;14:784
  25. Wallace JL, Dicay M, McKnight W, et al. Bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation. Alimen Pharmacol Ther. 1999;13:1675
  26. Suri S, Mönkkönen J, Tuskinen M, et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-induced gastrointestinal toxicity. Bone. 2001;29:336
  27. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016
  28. Loro L, Vintermyr OK, Johannessen AC. Apoptosis in normal and diseased oral tissues. Oral Dis. 2005;11:274
  29. Huerta S, Goulet EJ, Huerta-Yepez S, et al. Screening and detection of apoptosis. J Surg Res. 2007;139:143
  30. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342
  31. Leyvraz S, Hess U, Flesch G, et al. Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst. 1992;84:788
  32. Cremers SC, Papapoulo SE, Galderblom H, et al. Skeletal retention of bisphosphonate (palmidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metstasis. J Bone Mineral Res. 2005;20:1543
  33. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone. 2007;41:318
  34. King LE, Vieth R. Extraction and measurement of pamidronate from bone samples using automated pre-column derivatization, high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Appl. 1996;678:325
  35. Hoggarth CR, Bennett R, Daley-Yates PT. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int. 1991;49:416

 The project described was supported by Grant Number NIH 1 UL1 RR024156 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessary represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Reengineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp.

PII: S0278-2391(08)00094-3

doi: 10.1016/j.joms.2008.01.026

Journal of Oral and Maxillofacial Surgery
Volume 66, Issue 5 , Pages 839-847 , May 2008

Article Tools

* Image Usage & Resolution